Drug Trial Radar · NCT07388524
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
336
Planned (sponsor's estimate)
Start
Mar 2, 2027
Primary completion
Sep 30, 2032
Study completion Sep 30, 2032
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Feb 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.
Conditions
- Lung Non-Small Cell Carcinoma
Interventions
AtezolizumabBiological
Given IV
Atezolizumab and Recombinant Human HyaluronidaseBiological
Given SC
Biospecimen CollectionProcedure
Undergo collection of blood samples
Computed TomographyProcedure
Undergo CT
Patient ObservationOther
Undergo observation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free survivalTime frame: From randomization to disease recurrence, second lung primary, or death, assessed up to 10 years
Locations
171 sites in 1 country. Site status is shown where the registry gives one.
Kaiser Permanente-Anaheim
Anaheim, California · Recruiting
Kaiser Permanente-Baldwin Park
Baldwin Park, California · Recruiting
Kaiser Permanente-Bellflower
Bellflower, California · Recruiting
Tower Cancer Research Foundation
Beverly Hills, California · Recruiting
Kaiser Permanente-Fontana
Fontana, California · Recruiting
Kaiser Permanente South Bay
Harbor City, California · Recruiting
Kaiser Permanente-Irvine
Irvine, California · Recruiting
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California · Recruiting
Kaiser Permanente West Los Angeles
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Kaiser Permanente-Ontario
Ontario, California · Recruiting
Kaiser Permanente - Panorama City
Panorama City, California · Recruiting
Kaiser Permanente-Riverside
Riverside, California · Recruiting
Kaiser Permanente-San Diego Zion
San Diego, California · Recruiting
Kaiser Permanente-San Marcos
San Marcos, California · Recruiting
Cedars-Sinai Cancer - Tarzana
Tarzana, California · Recruiting
Torrance Memorial Physician Network - Cancer Care
Torrance, California · Recruiting
Kaiser Permanente-Woodland Hills
Woodland Hills, California · Recruiting
Beebe South Coastal Health Campus
Millville, Delaware · Recruiting
Helen F Graham Cancer Center
Newark, Delaware · Recruiting
Medical Oncology Hematology Consultants PA
Newark, Delaware · Recruiting
Beebe Health Campus
Rehoboth Beach, Delaware · Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
Illinois CancerCare-Bloomington
Bloomington, Illinois · Recruiting
Illinois CancerCare-Canton
Canton, Illinois · Recruiting
Illinois CancerCare-Carthage
Carthage, Illinois · Recruiting
John H Stroger Jr Hospital of Cook County
Chicago, Illinois · Recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois · Recruiting
Decatur Memorial Hospital
Decatur, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Illinois CancerCare-Eureka
Eureka, Illinois · Recruiting
Illinois CancerCare-Galesburg
Galesburg, Illinois · Recruiting
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois · Recruiting
Illinois CancerCare-Macomb
Macomb, Illinois · Recruiting
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois · Recruiting
Carle BroMenn Medical Center
Normal, Illinois · Recruiting
Carle Cancer Institute Normal
Normal, Illinois · Recruiting
Showing 40 of 171 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.